Patch Biosciences
Acquired
Machine-designed sequences for safer, more effective gene therapy
- Headquarters
- Albany, New York
- Employees
- 1–10
- Founded
- 2020
- Business Model
- B2B
- Website
- patch.bio
About
Patch Biosciences was a synthetic biology and machine learning company that built an AI platform for sequence design to engineer more effective, specific, and durable genetic medicines. The company developed machine learning models and downstream assays to engineer synthetic promoters and untranslated regions (UTRs) for gene therapy, cell therapy, and RNA therapeutics applications. Backed by Andreessen Horowitz Bio+Health, Casdin Capital, and S32, Patch was acquired by Ginkgo Bioworks in February 2024, with its AI/ML capabilities integrated into Ginkgo's genetic medicine platform to accelerate programs for biopharma partners including Pfizer and Biogen.